GlassScriptPhysician profile
Beth A Reynolds
NPI 1952477051
$923.05
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $98.42 · 2021: $23.04 · 2022: $381 · 2023: $80.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $80.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $80.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $124.84 | 2019-2022 | |
| Therapeuticsmd, INC. | $123.24 | 2019-2022 | |
| Abbvie INC. | $118.55 | 2019-2022 | |
| Pfizer INC. | $107.93 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.48 | 2019-2022 | |
| Aspira Women'S Health INC | $51.47 | 2022 | |
| Amarin Pharma, INC. | $51.02 | 2020 | |
| Myovant Sciences INC. | $43.98 | 2022 | |
| Coopersurgical, INC. | $40.61 | 2019-2022 | |
| Astellas Pharma US INC | $36.46 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $28.86 | 2019 | |
| Hologic Sales and Service, LLC | $28.44 | 2019 | |
| Scynexis, INC. | $25.89 | 2022 | |
| Organon LLC | $21.99 | 2023 | Nexplanon |
| Allergan, INC. | $17.00 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $13.57 | 2023 | Myfembree |
| Lupin INC. | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Reynolds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.